ASMR

• Grade 3 toxicity: 18% • RECIST complete response 49% • OS: 47,5% • F/u: 11,4 m. • SBRT • Dose: 36 Gy at 6 Gy/fx + cetuximab

• Multicenter study • Reirradiation (mean time 38 months) • Recurrent head and neck cancer • N=60, mediam age 69 y. • Period: 2007-2010

Lartigau et al. Radiotherapy and Oncology 109 (2013) 281–285